Some reports have confirmed that the differential expression of PD-L1 (B7-H1) in HCC patients may lead to different prognosis outcomes, and inhibition of the PD-L1 immunomodulatory pathways may contribute to antitumor effects in HCC [20–22]. The gene discussed is CD274; the disease is hepatocellular carcinoma.